Last update 30 Jun 2025

QH104

Overview

Basic Info

Drug Type
Universal CAR-T
Synonyms
Allogenic B7H3 CAR-γδT cell(Dushu Lake Hospital), QH 104, QH-104
Target
CD276
Action
modulators
Mechanism
CD276 modulators(CD276 antigen modulators), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsNervous System Diseases
Active Indication
Malignant glioma of brain
Inactive Indication
Glioblastoma Multiforme
Originator Organization
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
Active Organization
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
Inactive Organization
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with QH104
NCT06592092
/ RecruitingNot ApplicableIIT
Clinical Study of QH104 Cell Injection for the Treatment of Meningeal Metastases of B7H3+ Solid Tumors
NCT06018363
/ SuspendedPhase 1/2IIT
Allogenic B7H3-targeting CAR-γδT Cell Therapy in r/r GBM
100 Clinical Results associated with QH104
Login to view more data
100 Translational Medicine associated with QH104
Login to view more data
100 Patents (Medical) associated with QH104
Login to view more data
100 Deals associated with QH104
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Glioblastoma MultiformePhase 2
China
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
01 Jun 2023
Malignant glioma of brainPhase 2
China
The Fourth Affiliated Hospital of Soochow University (Suzhou Dushu Lake Hospital)
01 Jun 2023
Malignant glioma of brainPhase 2
China
Beijing Qinghui Liannuo Biotechnology Co Ltd.Beijing Qinghui Liannuo Biotechnology Co Ltd.
01 Jun 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06018363 (ESMO 12024 | ESMO 22024)
ManualManual
Phase 1
Recurrent Glioblastoma
CD276
7
mpaovwudrj(wbpszvmics) = None onncujosjz (jrmhktzoeo )
View more
Positive
13 Sep 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free